Conformational Restriction Leading to a Selective CB₂ Cannabinoid Receptor Agonist Orally Active Against Colitis

Conformational Restriction Leading to a Selective CB₂ Cannabinoid Receptor Agonist Orally Active Against Colitis 4-Oxo-1,4-dihydropyridines as Selective CB₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB₂Cannabinoid Receptors Agonists:  Synthesis, Pharmacological Properties and Molecular Modeling 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB₂Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB₂-Selective Cannabinoid Receptor Ligands:  Consequences in Receptor Affinity and Functionality New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3-carboxamide Derivatives as CB₂Selective Agonists 4-Oxo-1,4-dihydropyridines as Selective CB₂Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors